Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11850699,maximum concentration (C(max)),The maximum concentration (C(max)) of loratadine and descarboethoxyloratadine were approximately 4 ng ml(minus sign1) each.,Pharmacokinetics of Loratadine in Pediatric Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850699/),ml·ng,4,15556,DB00455,Loratadine
,11850699,elimination phase half-life,The elimination phase half-life of descarboethoxyloratadine averaged about 13.8 hr.,Pharmacokinetics of Loratadine in Pediatric Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850699/),h,13.8,15557,DB00455,Loratadine
,18840369,"Cmax,ss ratio","The Cmax,ss ratio was 111 (90% CI, 91-136) and area under the plasma concentration-time curve during a dosing interval (AUC0-tau) ratio had a value of 103 (90% CI, 91-117).","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,111,17539,DB00455,Loratadine
,18840369,"Cmax,ss ratios","Point estimates for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,111,17540,DB00455,Loratadine
,18840369,"Cmax,ss ratios","Point estimates for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,109,17541,DB00455,Loratadine
,15127620,flow rate,The flow rate was 1 mL.min-1.,Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127620/),[ml] / [min],1,17755,DB00455,Loratadine
,15127620,recoveries,The average method recoveries varied from 96% to 98%.,Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127620/),%,96,17756,DB00455,Loratadine
,15127620,recoveries,The average method recoveries varied from 96% to 98%.,Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127620/),%,98,17757,DB00455,Loratadine
,15127620,Relative bioavailabilities,Relative bioavailabilities were 107% +/- 17% and 100% +/- 14% respectively.,Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127620/),%,107,17758,DB00455,Loratadine
,15127620,Relative bioavailabilities,Relative bioavailabilities were 107% +/- 17% and 100% +/- 14% respectively.,Determination of loratadine in human plasma by HPLC with fluorescence detector and study on its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127620/),%,100,17759,DB00455,Loratadine
,16059990,ú,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,1.611,28489,DB00455,Loratadine
,16059990,t(max),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,1.611,28490,DB00455,Loratadine
,16059990,C(max),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [l],4.455,28491,DB00455,Loratadine
,16059990,AUC(0-t),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [h·l],58.50,28492,DB00455,Loratadine
,16059990,AUC(0-infinity),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [h·l],60.59,28493,DB00455,Loratadine
,16059990,t(1/2(ke)),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,20.303,28494,DB00455,Loratadine
,16059990,Ke,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),1/[h],0.0372,28495,DB00455,Loratadine
,16059990,CL,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[l] / [h],0.1838,28496,DB00455,Loratadine
,16059990,t(1/2),Desloratadine tablet is absorbed quicker in the 18 healthy volunteers than the reports and its peak blood concentration reached at 1.5 h after oral administration with t(1/2) 20 h.,[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,20,28497,DB00455,Loratadine
,12584158,efflux ratio,"Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.",P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584158/),,1,47722,DB00455,Loratadine
,25413271,zeta potential,The optimal SMEDDS was analysed and evaluated after emulsification in distilled water with diameter of 26.57 ± 0.71 nm and zeta potential of -30.5 ± 4.5 mV.,Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25413271/),mv,-,50231,DB00455,Loratadine
,25413271,zeta potential,The optimal SMEDDS was analysed and evaluated after emulsification in distilled water with diameter of 26.57 ± 0.71 nm and zeta potential of -30.5 ± 4.5 mV.,Dissolution evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery systems for pH-sensitive drug loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25413271/),mv,30.5,50232,DB00455,Loratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],27.8,53003,DB00455,Loratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],35.5,53004,DB00455,Loratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],137,53005,DB00455,Loratadine
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,6.47,53647,DB00455,Loratadine
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,13.8,53648,DB00455,Loratadine
,2966185,plasma Cmax,"For loratadine, the plasma Cmax was 30.5 ng/mL at 1.0 hour after dosing and the milk Cmax was 29.2 ng/mL in the 0 to 2 hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],30.5,61371,DB00455,Loratadine
,2966185,Cmax,"For loratadine, the plasma Cmax was 30.5 ng/mL at 1.0 hour after dosing and the milk Cmax was 29.2 ng/mL in the 0 to 2 hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],29.2,61372,DB00455,Loratadine
,2966185,milk-plasma AUC ratio,"Through 48 hours, the loratadine milk-plasma AUC ratio was 1.2 and 4.2 micrograms of loratadine was excreted in breast milk, which was 0.010% of the administered dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,1.2,61373,DB00455,Loratadine
,2966185,milk-plasma AUC ratio,"Through 48 hours, the loratadine milk-plasma AUC ratio was 1.2 and 4.2 micrograms of loratadine was excreted in breast milk, which was 0.010% of the administered dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,4.2,61374,DB00455,Loratadine
,2966185,plasma,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],18.6,61375,DB00455,Loratadine
,2966185,Cmax,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],18.6,61376,DB00455,Loratadine
,2966185,Cmax,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],16.0,61377,DB00455,Loratadine
,2966185,AUC ratio,"Through 48 hours, the mean milk-plasma descarboethoxyloratadine AUC ratio was 0.8 and a mean of 6.0 micrograms of descarboethoxyloratadine (7.5 micrograms loratadine equivalents) were excreted in the breast milk, or 0.019% of the administered loratadine dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),,0.8,61378,DB00455,Loratadine
,2966185,AUC ratio,"Through 48 hours, the mean milk-plasma descarboethoxyloratadine AUC ratio was 0.8 and a mean of 6.0 micrograms of descarboethoxyloratadine (7.5 micrograms loratadine equivalents) were excreted in the breast milk, or 0.019% of the administered loratadine dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,6.0,61379,DB00455,Loratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],7.17,65340,DB00455,Loratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],11.06,65341,DB00455,Loratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],14.59,65342,DB00455,Loratadine
,15932952,area under the plasma concentration-time curve (AUC),"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),,1.55,65343,DB00455,Loratadine
,15932952,area under the plasma concentration-time curve (AUC),"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),,3.32,65344,DB00455,Loratadine
,16962733,flow rate,The flow rate was 1 ml/min and the column temperature 45 degrees C.,Determination of loratadine and its active metabolite in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16962733/),[ml] / [min],1,65841,DB00455,Loratadine
,17425139,run time,A run time of 2.5 min for each sample makes it possible to analyze more than 400 human plasma samples per day.,Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425139/),min,2.5,86235,DB00455,Loratadine
,27886572,flow rate,"Separation was performed on an Xterra MS C18 column by isocratic elution using acetonitrile: water solution with 1‰ formic acid (90:10, v/v) as mobile phase at a flow rate of 0.3mL/min.",A rapid and sensitive UHPLC-MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886572/),[ml] / [min],0.3,92312,DB00455,Loratadine
,27886572,m,"A triple quadrupole mass spectrometer operating in the positive ion-switching electron spray ionization mode with selection reaction monitoring (SRM) was employed to determine 83b1 and IS transitions of m/z 321.82→147.84, 382.71→258.76 for 83b1 and Loratadine, respectively.",A rapid and sensitive UHPLC-MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886572/),,321.82,92313,DB00455,Loratadine
,27886572,m,"A triple quadrupole mass spectrometer operating in the positive ion-switching electron spray ionization mode with selection reaction monitoring (SRM) was employed to determine 83b1 and IS transitions of m/z 321.82→147.84, 382.71→258.76 for 83b1 and Loratadine, respectively.",A rapid and sensitive UHPLC-MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886572/),,382.71,92314,DB00455,Loratadine
,27886572,oral bioavailability,"The validated method was employed to study the bioavailability of 83b1 in rat by dosing with intravenous injection (1mg/kg) and gavage (10mg/kg), and the oral bioavailability of 83b1 in rat was calculated as 20.9±8.8%.",A rapid and sensitive UHPLC-MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886572/),%,20.9,92315,DB00455,Loratadine
,17620222,t((1/2)),"In five of the six subjects, DL was slowly eliminated (mean t((1/2)) = 19.5 h) and persisted in the plasma for 48-120 h post-dose.",Disposition of desloratadine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620222/),h,19.5,95646,DB00455,Loratadine
,17620222,t((1/2)),"This is in contrast to a t((1/2)) of approximately 110 h and quantifiable plasma DL concentrations for the entire 240-h sampling period in one subject, who was identified phenotypically as a poor metabolizer of DL.",Disposition of desloratadine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620222/),h,110,95647,DB00455,Loratadine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,431,98418,DB00455,Loratadine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,435,98419,DB00455,Loratadine
,15019035,flow rate,"Chromatographic separation was performed on a Hypersil CN column (150 mm x 5.0 mm, 5 microm) using a mixture of methanol, acetonitrile and phosphate buffer (pH 5.5; 0.01 mol/l) (35:35:30, v/v/v) as mobile phase delivered at a flow rate of 0.8 ml/min.",High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019035/),[ml] / [min],0.8,102129,DB00455,Loratadine
,15019035,recovery,The recovery of desloratadine from dog plasma ranged from 78.8 to 82.0%.,High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019035/),%,78.8 to 82.0,102130,DB00455,Loratadine
,29694333,relative bioavailability,"Rat pharmacokinetic experiments showed that the oral bioavailability of the suspension film was significantly higher than that of the commercial tablets, and the relative bioavailability of the suspension film was 175%.",Effect of taste masking technology on fast dissolving oral film: dissolution rate and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29694333/),%,175,102157,DB00455,Loratadine
≥,26446005,half-life (t 1/2),The individuals with a 3-OH-desloratadine-to-desloratadine exposure ratio lower than 10 % or a desloratadine half-life (t 1/2) of ≥50 h were supposed to be DSM.,Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446005/),h,50,108420,DB00455,Loratadine
,1685361,Serum elimination half-life,"Serum elimination half-life values differ greatly from 1 H1-RA to another, and are 24 h or less for terfenadine, astemizole, loratadine, cetirizine, azelastine and ebastine, and the active metabolites of terfenadine, loratadine and ebastine.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),h,24,110704,DB00455,Loratadine
,1685361,serum elimination half-life,"The active metabolite of azelastine (demethylazelastine) has a serum elimination half-life value of about 2 days, while that of astemizole (demethyl-astemizole) has a value of 9.5 days.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),d,2,110705,DB00455,Loratadine
,1685361,serum elimination half-life,"The active metabolite of azelastine (demethylazelastine) has a serum elimination half-life value of about 2 days, while that of astemizole (demethyl-astemizole) has a value of 9.5 days.",Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685361/),d,9.5,110706,DB00455,Loratadine
,15953705,flow rate,Chromatographic separation was performed on an ODS column at flow rate of 0.2 ml/min.,Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[ml] / [min],0.2,111725,DB00455,Loratadine
,15953705,total chromatographic run time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,10.5,111726,DB00455,Loratadine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,7.1,111727,DB00455,Loratadine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,6.2,111728,DB00455,Loratadine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,2.2,111729,DB00455,Loratadine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],10,111730,DB00455,Loratadine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],50,111731,DB00455,Loratadine
,20206796,T(max),"Loratadine 10-mg tablets have been reported to be rapidly absorbed after once-daily administration for 10 days in healthy adult subjects, with a T(max) of 1.3 hours for loratadine and 2.5 hours for its major active metabolite, descarboethoxyloratadine.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,1.3,114735,DB00455,Loratadine
,20206796,T(max),"Loratadine 10-mg tablets have been reported to be rapidly absorbed after once-daily administration for 10 days in healthy adult subjects, with a T(max) of 1.3 hours for loratadine and 2.5 hours for its major active metabolite, descarboethoxyloratadine.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,2.5,114736,DB00455,Loratadine
,20206796,t(1/2),"The t(1/2) in normal adult subjects has been reported to be 8.4 hours (range, 3-20 hours) for loratadine and 28 hours for its metabolite.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,8.4,114737,DB00455,Loratadine
,20206796,t(1/2),"The t(1/2) in normal adult subjects has been reported to be 8.4 hours (range, 3-20 hours) for loratadine and 28 hours for its metabolite.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,28,114738,DB00455,Loratadine
,20206796,ke,"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hour],0.19,114739,DB00455,Loratadine
,20206796,t(1/2),"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,3.65,114740,DB00455,Loratadine
,20206796,t(1/2),"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hours],1.31,114741,DB00455,Loratadine
,20206796,absorption rate constant,"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,3.65,114742,DB00455,Loratadine
,20206796,absorption rate constant,"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hours],1.31,114743,DB00455,Loratadine
,20206796,absorption t(1/2),"Population ke, t(1/2), absorption rate constant, and absorption t(1/2) were 0.19 hour(-1), 3.65 hours, 1.31 hours(-1), and 0.53 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,0.53,114744,DB00455,Loratadine
,20206796,Distribution rate constant,"Distribution rate constant, redistribution rate constant, and lag time were 0.31 hour(-1), 0.02 hour(-1), and 0.32 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hour],0.31,114745,DB00455,Loratadine
,20206796,redistribution rate constant,"Distribution rate constant, redistribution rate constant, and lag time were 0.31 hour(-1), 0.02 hour(-1), and 0.32 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hour],0.02,114746,DB00455,Loratadine
,20206796,lag time,"Distribution rate constant, redistribution rate constant, and lag time were 0.31 hour(-1), 0.02 hour(-1), and 0.32 hour, respectively.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,0.32,114747,DB00455,Loratadine
,20206796,C(max),"The noncompartmental estimate for C(max) was 3.02 ng/mL, which occurred at 1.30 hours, with a t(1/2) of 5 hours and a k(e) of 0.14 hour(-1).","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),[ng] / [ml],3.02,114748,DB00455,Loratadine
,20206796,t(1/2),"The noncompartmental estimate for C(max) was 3.02 ng/mL, which occurred at 1.30 hours, with a t(1/2) of 5 hours and a k(e) of 0.14 hour(-1).","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,5,114749,DB00455,Loratadine
,20206796,k(e),"The noncompartmental estimate for C(max) was 3.02 ng/mL, which occurred at 1.30 hours, with a t(1/2) of 5 hours and a k(e) of 0.14 hour(-1).","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),1/[hour],0.14,114750,DB00455,Loratadine
,20206796,t(1/2),"The population t(1/2) for loratadine was 3.65 hours in this group of healthy white Jordanian male volunteers, shorter than that observed in previous research.","A retrospective, open-label analysis of the population pharmacokinetics of a single 10-mg dose of loratadine in healthy white Jordanian male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206796/),h,3.65,114751,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,5.62,117071,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,4.08,117072,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,4.29,117073,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,2.6,117074,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),,3.26,117075,DB00455,Loratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),,3.27,117076,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],133.05,117077,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],258.07,117078,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],104.5,117079,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],188.62,117080,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],94.33,117081,DB00455,Loratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],187.75,117082,DB00455,Loratadine
,18622814,total apparent clearance,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],61.46,117083,DB00455,Loratadine
,18622814,total apparent clearance,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],15.97,117084,DB00455,Loratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],57.3,117085,DB00455,Loratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],14.22,117086,DB00455,Loratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],43.79,117087,DB00455,Loratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],12.89,117088,DB00455,Loratadine
,18622814,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of loratadine and desloratadine was significantly (p<0.05) greater following drug administration at 9 HALO (456.75 and 1550.57 (ng/mL) .,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],456.75,117089,DB00455,Loratadine
,18622814,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of loratadine and desloratadine was significantly (p<0.05) greater following drug administration at 9 HALO (456.75 and 1550.57 (ng/mL) .,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],1550.57,117090,DB00455,Loratadine
,20662320,absolute bioavailability,"Consequently, the absolute bioavailability of loratadine in the presence of silybinin (1.5 and 6 mg x kg(-1)) was 8.6-10.2%, which was significantly (1.5 mg x kg(-1), P < 0.05; 6 mg x kg(-1), P < 0.01) enhanced compared to that in oral control group (5.8%).","Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662320/),%,8.6-10.2,120916,DB00455,Loratadine
,20662320,absolute bioavailability,"Consequently, the absolute bioavailability of loratadine in the presence of silybinin (1.5 and 6 mg x kg(-1)) was 8.6-10.2%, which was significantly (1.5 mg x kg(-1), P < 0.05; 6 mg x kg(-1), P < 0.01) enhanced compared to that in oral control group (5.8%).","Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662320/),%,5.8,120917,DB00455,Loratadine
,32570975,"gastric half-life (t1/2,G)","The luminal behavior of one immediate-release (IR) tablet of 10 mg of loratadine was tested under four different fasted state test conditions in the GIS: (i) with 250 mL of water and applying a predetermined gastric half-life (t1/2,G) of 15 min; (ii) with 250 mL of water and applying a t1/2,G of 30 min; (iii) with 250 mL of Coca-Cola® and a t1/2,G of 15 min; (iv) with 250 mL of Coca-Cola® and a t1/2,G of 30 min.",Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32570975/),min,15,122476,DB00455,Loratadine
,32570975,"t1/2,G","The luminal behavior of one immediate-release (IR) tablet of 10 mg of loratadine was tested under four different fasted state test conditions in the GIS: (i) with 250 mL of water and applying a predetermined gastric half-life (t1/2,G) of 15 min; (ii) with 250 mL of water and applying a t1/2,G of 30 min; (iii) with 250 mL of Coca-Cola® and a t1/2,G of 15 min; (iv) with 250 mL of Coca-Cola® and a t1/2,G of 30 min.",Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32570975/),min,30,122477,DB00455,Loratadine
,32570975,"t1/2,G","The luminal behavior of one immediate-release (IR) tablet of 10 mg of loratadine was tested under four different fasted state test conditions in the GIS: (i) with 250 mL of water and applying a predetermined gastric half-life (t1/2,G) of 15 min; (ii) with 250 mL of water and applying a t1/2,G of 30 min; (iii) with 250 mL of Coca-Cola® and a t1/2,G of 15 min; (iv) with 250 mL of Coca-Cola® and a t1/2,G of 30 min.",Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32570975/),min,15,122478,DB00455,Loratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.17,126203,DB00455,Loratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.68,126204,DB00455,Loratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.87,126205,DB00455,Loratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.00,126206,DB00455,Loratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],77.9,126207,DB00455,Loratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],80.0,126208,DB00455,Loratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],90.6,126209,DB00455,Loratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],68.8,126210,DB00455,Loratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],1.93,126211,DB00455,Loratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.79,126212,DB00455,Loratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.20,126213,DB00455,Loratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.45,126214,DB00455,Loratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],32.1,126215,DB00455,Loratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],47.5,126216,DB00455,Loratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],37.1,126217,DB00455,Loratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],41.1,126218,DB00455,Loratadine
,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,0.9,129595,DB00455,Loratadine
> or =,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,3,129596,DB00455,Loratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],0.4,129597,DB00455,Loratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],1-1.2,129598,DB00455,Loratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],5.4-5.8,129599,DB00455,Loratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],49,129600,DB00455,Loratadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,50-65,129601,DB00455,Loratadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,33,129602,DB00455,Loratadine
,11502723,maximal human plasma concentration,"Loratadine did not inhibit CYP1A2 or CYP3A4 at concentrations up to 3829 ng/ml, which is approximately 815-fold greater than the expected maximal human plasma concentration (4.7 +/- 2.7 ng/ml) following the recommended dose of 10 mg/day.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],4.7,132881,DB00455,Loratadine
,11502723,IC(50),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,0.76,132882,DB00455,Loratadine
,11502723,IC(50),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],291,132883,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,0.61,132884,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],234,132885,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,8.1,132886,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],3100,132887,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,2.7,132888,DB00455,Loratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],1034,132889,DB00455,Loratadine
,10868558,peak plasma concentrations,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[ng] / [ml],7.78,143825,DB00455,Loratadine
,10868558,peak plasma concentrations,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[ng] / [ml],5.09,143826,DB00455,Loratadine
,10868558,areas under the plasma concentration-time curve to the last quantifiable time point,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[h·ng] / [ml],16.7,143827,DB00455,Loratadine
,10868558,areas under the plasma concentration-time curve to the last quantifiable time point,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[h·ng] / [ml],87.2,143828,DB00455,Loratadine
,15189594,recovery,The mean recovery of E2020 from human plasma is 99.4% +/- 6.3% (ranging 93.4-102.6%).,"Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),%,99.4,147102,DB00455,Loratadine
,15189594,T(max),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,3.10,147103,DB00455,Loratadine
,15189594,t((1/2)),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,65.7,147104,DB00455,Loratadine
,15189594,C(max),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),[ng] / [ml],10.1,147105,DB00455,Loratadine
,15189594,MRT,"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,89.4,147106,DB00455,Loratadine
,15189594,CL/F,"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),[l] / [h],9.9,147107,DB00455,Loratadine
,11243504,half-life,"Desloratadine has a half-life of 21-24 h, permitting once-daily dosing.",The pharmacologic profile of desloratadine: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243504/),h,21-24,148009,DB00455,Loratadine
,12169041,Maximum mean plasma concentration (C(max)),Maximum mean plasma concentration (C(max)) was 3.53 microg/L in fed compared with 3.30 microg/L in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [l],3.53,149724,DB00455,Loratadine
,12169041,Maximum mean plasma concentration (C(max)),Maximum mean plasma concentration (C(max)) was 3.53 microg/L in fed compared with 3.30 microg/L in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [l],3.30,149725,DB00455,Loratadine
,12169041,Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)),Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)) mean values were 61.0 microg/L x h in fed and 61.9 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],61.0,149726,DB00455,Loratadine
,12169041,Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)),Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)) mean values were 61.0 microg/L x h in fed and 61.9 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],61.9,149727,DB00455,Loratadine
,12169041,AUC extrapolated to infinity (AUC(infinity )),Fed individuals had mean AUC extrapolated to infinity (AUC(infinity )) of 62.5 microg/L x h compared with 63.5 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],62.5,149728,DB00455,Loratadine
,12169041,AUC extrapolated to infinity (AUC(infinity )),Fed individuals had mean AUC extrapolated to infinity (AUC(infinity )) of 62.5 microg/L x h compared with 63.5 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],63.5,149729,DB00455,Loratadine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,few,153583,DB00455,Loratadine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,9,153584,DB00455,Loratadine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),h,20 to 25,153585,DB00455,Loratadine
,2892445,serum elimination half-life,"The serum elimination half-life values of these agents are variable: a few hours for terfenadine and triprolidine; about 9 hours for cetirizine, azatadine, and loratadine; from 20 to 25 hours for hydroxyzine, chlorpheniramine, and brompheniramine; and from 5 to 14 days for astemizole.",The comparative pharmacokinetics of H1-receptor antagonists. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),d,5 to 14,153586,DB00455,Loratadine
,2892445,apparent volumes of distribution,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[l] / [kg],3.4 to 18.5,153587,DB00455,Loratadine
,2892445,total body clearances,"Regardless of the age of patients, for most of the H1-receptor antagonists the apparent volumes of distribution and total body clearances appear to be large (3.4 to 18.5 L/kg and 4.4 to 32.1 mL/min/kg, respectively).",The comparative pharmacokinetics of H1-receptor antagonists. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892445/),[ml] / [kg·min],4.4 to 32.1,153588,DB00455,Loratadine
,11358228,flow-rate,"Chromatography was performed on a Phenomenex Luna C18 (2) 5-microm, 150x2.1-mm column with a mobile phase consisting of acetonitrile-0.1% formic acid using gradient elution (10 to 90% acetonitrile in 2 min) at a flow-rate of 0.3 ml/min.",Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358228/),[ml] / [min],0.3,155800,DB00455,Loratadine
,11358228,recovery,"The mean recovery for loratadine and descarboethoxyloratadine was 61 and 100%, respectively, with a lower limit of quantification at 0.10 ng/ml for both the analyte and its metabolite.",Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358228/),%,61,155801,DB00455,Loratadine
,11358228,recovery,"The mean recovery for loratadine and descarboethoxyloratadine was 61 and 100%, respectively, with a lower limit of quantification at 0.10 ng/ml for both the analyte and its metabolite.",Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11358228/),%,100,155802,DB00455,Loratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [l],3.98,155843,DB00455,Loratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [l],1.99,155844,DB00455,Loratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,3.17,155845,DB00455,Loratadine
,12169042,t(max),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,3.17,155846,DB00455,Loratadine
,12169042,t(max),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,4.76,155847,DB00455,Loratadine
,12169042,area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)),The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 micro g/L x h for desloratadine and 32.3 micro g/L x h for 3-OH desloratadine.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [h·l],56.9,155848,DB00455,Loratadine
,12169042,area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)),The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 micro g/L x h for desloratadine and 32.3 micro g/L x h for 3-OH desloratadine.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [h·l],32.3,155849,DB00455,Loratadine
,12169042,half-lives (t((1/2))),"The mean half-lives (t((1/2))) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,26.8,155850,DB00455,Loratadine
,12169042,half-lives (t((1/2))),"The mean half-lives (t((1/2))) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,36,155851,DB00455,Loratadine
,12169042,half-life,The 27-hour half-life of desloratadine permits once daily administration.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,27,155852,DB00455,Loratadine
,16504450,absolute recovery,The average absolute recovery of olanzapine from spiked plasma samples was 85.5+/-1.9%.,Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504450/),%,85.5,157836,DB00455,Loratadine
,16504450,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504450/),min,2.0,157837,DB00455,Loratadine
,14520518,wheal area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),mm(2),79.3,158644,DB00455,Loratadine
,14520518,flare area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),cm(2),26.6,158645,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],27-54.3,161644,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],115.7,161645,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],23.4,161646,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],7.7,161647,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],49.8,161648,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],902.1,161649,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],40.9,161650,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],2.6,161651,DB00455,Loratadine
,15663222,AUDRC,"The AUDRC(27-54.3 mmol/l.) for wheal and flare of mizolastine was 115.7, 23.4, 7.7, 49.8 and 902.1, 40.9, 2.6, 46.9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively.",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[ln·mmol] / [l)·mm2],46.9,161652,DB00455,Loratadine
,15663222,AUDRC,"Compared with loratadine [116.2, 80.2, 49.7, 71.9 and 957.6, 495.3, 153.5, 205.9 ln (mmol/L) x mm2], mizolastine decreased AUDRC(2.7 - 54.3 mmol/L significantly (P < 0.01).",[Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15663222/),[mM] / [l],2.7 - 54.3,161653,DB00455,Loratadine
,12169040,half-life (t((1/2))),The half-life (t((1/2))) ranged from 21.2 to 24.1 hours.,Desloratadine demonstrates dose proportionality in healthy adults after single doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169040/),h,21.2 to 24.1,163902,DB00455,Loratadine
,2958516,Tmax,Steady-state plasma L Cmax concentrations were reached at 1.5 hour (Tmax) after each dose.,Loratadine: multiple-dose pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),h,1.5,170417,DB00455,Loratadine
,2958516,steady-state Cmax,DCL steady-state Cmax values ranged 26 to 29 ng/mL at a Tmax ranging from 1.8 to 3 hours.,Loratadine: multiple-dose pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),[ng] / [ml],26 to 29,170418,DB00455,Loratadine
,2958516,Tmax,DCL steady-state Cmax values ranged 26 to 29 ng/mL at a Tmax ranging from 1.8 to 3 hours.,Loratadine: multiple-dose pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),h,1.8 to 3,170419,DB00455,Loratadine
,2958516,"AUC at steady state, AUC tau","The AUC at steady state, AUC tau, was 80 to 96 and 349 to 421 h X ng/mL for L and DCL, respectively.",Loratadine: multiple-dose pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),[h·ng] / [ml],80 to 96,170420,DB00455,Loratadine
,2958516,"AUC at steady state, AUC tau","The AUC at steady state, AUC tau, was 80 to 96 and 349 to 421 h X ng/mL for L and DCL, respectively.",Loratadine: multiple-dose pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),[h·ng] / [ml],349 to 421,170421,DB00455,Loratadine
,2958516,Ra,"Ra values for L and DCL after the fifth dose were 1.4 and 1.9, respectively, indicating that there is little accumulation of either L or DCL after a multiple (once-a-day) dosage regimen.",Loratadine: multiple-dose pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),,1.4,170422,DB00455,Loratadine
,2958516,Ra,"Ra values for L and DCL after the fifth dose were 1.4 and 1.9, respectively, indicating that there is little accumulation of either L or DCL after a multiple (once-a-day) dosage regimen.",Loratadine: multiple-dose pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),,1.9,170423,DB00455,Loratadine
,2958516,t1/2 beta at steady state,"The t1/2 beta at steady state were 14.4 and 18.7 hours for L and DCL, respectively, which were similar to those reported following a single-dose L administration.",Loratadine: multiple-dose pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),h,14.4,170424,DB00455,Loratadine
,2958516,t1/2 beta at steady state,"The t1/2 beta at steady state were 14.4 and 18.7 hours for L and DCL, respectively, which were similar to those reported following a single-dose L administration.",Loratadine: multiple-dose pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2958516/),h,18.7,170425,DB00455,Loratadine
,15382318,flow-rate,The reconstituted solution was injected into an HPLC system and was subjected to reverse-phase HPLC on a 5-microm ODS-3 column at a flow-rate of 0.2 ml/min.,A validated HPLC-ESI-MS method for the determination of loratadine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15382318/),[ml] / [min],0.2,179364,DB00455,Loratadine
more,15382318,extraction recovery,The extraction recovery of loratadine was more than 80%.,A validated HPLC-ESI-MS method for the determination of loratadine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15382318/),%,80,179365,DB00455,Loratadine
,12852841,maximum concentration (C(max)),Mean maximum concentration (C(max)) was found (17+/-14) microg/L for LOR at 1.2 h and (16+/-9) microg/L for DCL at 1.5 h.,Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[μg] / [l],17,191038,DB00455,Loratadine
,12852841,maximum concentration (C(max)),Mean maximum concentration (C(max)) was found (17+/-14) microg/L for LOR at 1.2 h and (16+/-9) microg/L for DCL at 1.5 h.,Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[μg] / [l],16,191039,DB00455,Loratadine
,12852841,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),"Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was (47+/-49) microg x h x L(-1) for LOR and (181+/-122) microg x h x L(-1) for DCL, respectively.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[h·μg] / [l],47,191040,DB00455,Loratadine
,12852841,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),"Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was (47+/-49) microg x h x L(-1) for LOR and (181+/-122) microg x h x L(-1) for DCL, respectively.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[h·μg] / [l],181,191041,DB00455,Loratadine
,12852841,apparent elimination half-life (T1/2),"The apparent elimination half-life (T1/2) of LOR was (6+/-4) h, and that of DCL was (13.4+/-2.6) h.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),h,6,191042,DB00455,Loratadine
,12852841,apparent elimination half-life (T1/2),"The apparent elimination half-life (T1/2) of LOR was (6+/-4) h, and that of DCL was (13.4+/-2.6) h.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),h,13.4,191043,DB00455,Loratadine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,1.9,191563,DB00455,Loratadine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,13,191564,DB00455,Loratadine
greater,12649305,Ki,The Ki values for SCH 79687 at histamine H1 and H2 receptors were greater than 1 microM.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μM,1,191565,DB00455,Loratadine
,12649305,pA2,The pA2 value for SCH 79687 in the GP ileum electrical field-stimulated (EFS) contraction was 9.6 +/- 0.3.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.6,191566,DB00455,Loratadine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.4,191567,DB00455,Loratadine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,10.1,191568,DB00455,Loratadine
,12649305,ED50,SCH 79687 (ED50 = 0.3 mg/kg i.v.) attenuated (R)-alpha-methylhistamine inhibition of sympathetic hypertensive responses in the GP.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),[mg] / [kg],0.3,191569,DB00455,Loratadine
greater,12649305,plasma Cmax,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,1.5,191570,DB00455,Loratadine
greater,12649305,area under the curve,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,12.1,191571,DB00455,Loratadine
,19889586,flow rate,"Sertaconazole and IS was separated on a C18 column using isocratic elution with a mobile phase of methanol: 0.2% formic acid aqueous solution (70:30, v/v,) at the flow rate of 0.2 mL/min.",A validated LC-MS/MS method for determination of sertaconazole nitrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889586/),[ml] / [min],0.2,193634,DB00455,Loratadine
,19889586,m,The transition monitored were m/z 439 [M+H](+)-->m/z 181 for sertaconazole and m/z 383[M+H]+ --> m/z 337 for IS.,A validated LC-MS/MS method for determination of sertaconazole nitrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889586/),,439,193635,DB00455,Loratadine
,19889586,extraction recoveries,The extraction recoveries ranged from 60% to 70% across the calibration curve range.,A validated LC-MS/MS method for determination of sertaconazole nitrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889586/),%,60,193636,DB00455,Loratadine
,19889586,extraction recoveries,The extraction recoveries ranged from 60% to 70% across the calibration curve range.,A validated LC-MS/MS method for determination of sertaconazole nitrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889586/),%,70,193637,DB00455,Loratadine
,2960701,Cmax,"Loratadine was rapidly absorbed, reaching Cmax values (4.7, 10.8, and 26.1 ng/mL) at 1.5, 1.0 and 1.2 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],4.7,195664,DB00455,Loratadine
,2960701,Cmax,"Loratadine was rapidly absorbed, reaching Cmax values (4.7, 10.8, and 26.1 ng/mL) at 1.5, 1.0 and 1.2 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],10.8,195665,DB00455,Loratadine
,2960701,Cmax,"Loratadine was rapidly absorbed, reaching Cmax values (4.7, 10.8, and 26.1 ng/mL) at 1.5, 1.0 and 1.2 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],26.1,195666,DB00455,Loratadine
,2960701,t1/2 beta,The loratadine t1/2 beta ranged from 7.8 to 11.0 hours.,Pharmacokinetics and dose proportionality of loratadine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),h,7.8 to 11.0,195667,DB00455,Loratadine
,2960701,Cmax,"Descarboethoxyloratadine reached Cmax values (4.0, 9.9, and 16.0 ng/mL) at 3.7, 1.5, and 2.0 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],4.0,195668,DB00455,Loratadine
,2960701,Cmax,"Descarboethoxyloratadine reached Cmax values (4.0, 9.9, and 16.0 ng/mL) at 3.7, 1.5, and 2.0 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],9.9,195669,DB00455,Loratadine
,2960701,Cmax,"Descarboethoxyloratadine reached Cmax values (4.0, 9.9, and 16.0 ng/mL) at 3.7, 1.5, and 2.0 hours for the 10-, 20-, and 40-mg doses, respectively.",Pharmacokinetics and dose proportionality of loratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),[ng] / [ml],16.0,195670,DB00455,Loratadine
,2960701,t1/2 beta,Its t1/2 beta ranged from 17 to 24 hours.,Pharmacokinetics and dose proportionality of loratadine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960701/),h,17 to 24,195671,DB00455,Loratadine
,11240972,area under the plasma concentration-time curve,"Concomitant nefazodone treatment markedly increased the dose interval area under the plasma concentration-time curve of both terfenadine (mean value, 17.3 +/- 8.5 ng.",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ng,17.3,197542,DB00455,Loratadine
,11240972,area under the plasma concentration-time curve,"h/mL; P <.001) and moderately increased the dose interval area under the plasma concentration-time curve of both loratadine (mean value, 31.5 +/- 27.9 ng.",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ng,31.5,197543,DB00455,Loratadine
,11240972,QTc,"Similarly, the mean QTc was unchanged with loratadine alone; however, it was prolonged with concomitant nefazodone and loratadine (21.6 ms [13.7, 29.4 ms]; P <.05).",Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240972/),ms,21.6,197544,DB00455,Loratadine
,12830717,detection limit,The detection limit of donepezil was 0.1 microgram.,[Determination of donepezil in human plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830717/),μg,0.1,198736,DB00455,Loratadine
more,12830717,recovery,The average recovery was more than 90%.,[Determination of donepezil in human plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830717/),%,90,198737,DB00455,Loratadine
,12169044,maximum corrected QT (QT(c)) interval,The maximum corrected QT (QT(c)) interval was 445 msec for both treatments.,Lack of clinically relevant interaction between desloratadine and erythromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169044/),ms,445,203340,DB00455,Loratadine
,17488362,C(max),Plasma desloratadine C(max) occurred at a median of 2.0 h after dosing in both age groups.,Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,2.0,225579,DB00455,Loratadine
,17488362,t(1/2),"Arithmetic (and harmonic) mean t(1/2) (h) values for each group, respectively, were 16.4 (13.9) and 19.4 (15.8).",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,16.4,225580,DB00455,Loratadine
,17488362,t(1/2),"Arithmetic (and harmonic) mean t(1/2) (h) values for each group, respectively, were 16.4 (13.9) and 19.4 (15.8).",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,19.4,225581,DB00455,Loratadine
,17488362,AUC(last),"Exposure to desloratadine was similar in both the younger and older age groups, with a median AUC(last) of 38.8 and 38.2 ng ml(-1) h, respectively.",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),[h·ng] / [ml],38.8,225582,DB00455,Loratadine
,17488362,AUC(last),"Exposure to desloratadine was similar in both the younger and older age groups, with a median AUC(last) of 38.8 and 38.2 ng ml(-1) h, respectively.",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),[h·ng] / [ml],38.2,225583,DB00455,Loratadine
,19402342,limit of detection (LOD),The limit of detection (LOD) of ticlopidine hydrochloride was 0.5 ng/mL.,Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402342/),[ng] / [ml],0.5,225979,DB00455,Loratadine
more,19402342,extraction recovery,The extraction recovery of ticlopidine hydrochloride was more than 80%.,Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402342/),%,80,225980,DB00455,Loratadine
,26922577,flow rate,"The analyte and ISTD were extracted by solid-phase extraction and chromatographic separation was achieved on Gemini NX- Reverse Phase C18 (50 × 4.6mm; 5 μ) using mobile phase mixture of 5mM ammonium formate buffer in water (pH 3.5 ± 0.1 with formic acid), and acetonitrile (20:80 v/v), at a flow rate of 0.400 mL/min with injection volume of 10 μL.",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),[ml] / [min],0.400,230057,DB00455,Loratadine
,26922577,retention time,"LTD and ISTD were detected at m/z 383.3 → 337.4 and 388.4 → 337.3 with retention time of 2.62 and 2.59 min, respectively.",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),min,2.62,230058,DB00455,Loratadine
,26922577,retention time,"LTD and ISTD were detected at m/z 383.3 → 337.4 and 388.4 → 337.3 with retention time of 2.62 and 2.59 min, respectively.",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),min,2.59,230059,DB00455,Loratadine
,26922577,process efficiency,"The extraction method displayed a mean process efficiency of 63.25 and 65.47% for LTD and ISTD, respectively.",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),%,63.25,230060,DB00455,Loratadine
,26922577,process efficiency,"The extraction method displayed a mean process efficiency of 63.25 and 65.47% for LTD and ISTD, respectively.",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),%,65.47,230061,DB00455,Loratadine
,26922577,Cmax,"The validated method when successfully applied for quantification of LTD in rat plasma revealed enhanced bioavailability of orally administered LTD-loaded self-nanoemulsifying drug delivery system (SNEDDS) (Cmax, 466.65 ± 18.94 ng/mL and AUC0-t 633.00 ± 12.44 ng-h/mL) over LTD-suspension (Cmax, 104.75 ± 2.87 ng/mL and AUC0-t 287.00 ± 9.11 ng-h/mL).",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),[ng] / [ml],466.65,230062,DB00455,Loratadine
,26922577,AUC0-t,"The validated method when successfully applied for quantification of LTD in rat plasma revealed enhanced bioavailability of orally administered LTD-loaded self-nanoemulsifying drug delivery system (SNEDDS) (Cmax, 466.65 ± 18.94 ng/mL and AUC0-t 633.00 ± 12.44 ng-h/mL) over LTD-suspension (Cmax, 104.75 ± 2.87 ng/mL and AUC0-t 287.00 ± 9.11 ng-h/mL).",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),[ng-h] / [ml],633.00,230063,DB00455,Loratadine
,26922577,Cmax,"The validated method when successfully applied for quantification of LTD in rat plasma revealed enhanced bioavailability of orally administered LTD-loaded self-nanoemulsifying drug delivery system (SNEDDS) (Cmax, 466.65 ± 18.94 ng/mL and AUC0-t 633.00 ± 12.44 ng-h/mL) over LTD-suspension (Cmax, 104.75 ± 2.87 ng/mL and AUC0-t 287.00 ± 9.11 ng-h/mL).",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),[ng] / [ml],104.75,230064,DB00455,Loratadine
,26922577,AUC0-t,"The validated method when successfully applied for quantification of LTD in rat plasma revealed enhanced bioavailability of orally administered LTD-loaded self-nanoemulsifying drug delivery system (SNEDDS) (Cmax, 466.65 ± 18.94 ng/mL and AUC0-t 633.00 ± 12.44 ng-h/mL) over LTD-suspension (Cmax, 104.75 ± 2.87 ng/mL and AUC0-t 287.00 ± 9.11 ng-h/mL).",LC-ESI-MS/MS estimation of loratadine-loaded self-nanoemulsifying drug delivery systems in rat plasma: Pharmacokinetic evaluation and computer simulations by GastroPlus™. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922577/),[ng-h] / [ml],287.00,230065,DB00455,Loratadine
,11295678,half-life,"Desloratadine is rapidly absorbed, has dose-proportional pharmacokinetics, and has a half-life of 27 hours.","Desloratadine: A new, nonsedating, oral antihistamine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295678/),h,27,230937,DB00455,Loratadine
,32084574,polydispersity index,"Loratadine nanosuspension displayed a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of -22.05 mV.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),,0.16,234418,DB00455,Loratadine
,32084574,zeta potential,"Loratadine nanosuspension displayed a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of -22.05 mV.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),m,22.05,234419,DB00455,Loratadine
,32084574,flux,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[μg] / [(cm)^2·h],1.49,234420,DB00455,Loratadine
,32084574,permeability coefficient,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[μg] / [(cm)^2·h],1.49,234421,DB00455,Loratadine
,32084574,flux,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[cm] / [h],0.017,234422,DB00455,Loratadine
,32084574,permeability coefficient,"NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively.","Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32084574/),[cm] / [h],0.017,234423,DB00455,Loratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,12.21,248271,DB00455,Loratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.39-17.03,248272,DB00455,Loratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,10.68,248273,DB00455,Loratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,6.96,248274,DB00455,Loratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.52,248275,DB00455,Loratadine
,17497754,flow rate,The mobile phase containing sodium dodecyl sulfate (SDS) as ion pairing agent was pumped at a flow rate of 1 mL/min.,Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497754/),[ml] / [min],1,257365,DB00455,Loratadine
,2965043,maximum plasma concentration,"Loratadine was rapidly absorbed, reaching a maximum plasma concentration of 50.5 ng/ml at 1.5 h after dosing.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[ng] / [ml],50.5,261832,DB00455,Loratadine
,2965043,disposition half-lives,"The disposition half-lives of loratadine in the distribution and elimination phases were 1.5 and 18.2 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,1.5,261833,DB00455,Loratadine
,2965043,disposition half-lives,"The disposition half-lives of loratadine in the distribution and elimination phases were 1.5 and 18.2 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,18.2,261834,DB00455,Loratadine
,2965043,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve, was 146.7 h.ng/ml.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[h·ng] / [ml],146.7,261835,DB00455,Loratadine
,2965043,maximum plasma concentration,Descarboethoxyloratadine had a maximum plasma concentration of 28.0 ng/ml at 2.9 h post-dose and an area under the concentration-time curve of 394.9 h.ng/ml.,The pharmacokinetics of loratadine in normal geriatric volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[ng] / [ml],28.0,261836,DB00455,Loratadine
,2965043,area under the concentration-time curve,Descarboethoxyloratadine had a maximum plasma concentration of 28.0 ng/ml at 2.9 h post-dose and an area under the concentration-time curve of 394.9 h.ng/ml.,The pharmacokinetics of loratadine in normal geriatric volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[h·ng] / [ml],394.9,261837,DB00455,Loratadine
,2965043,disposition half-lives,"Its disposition half-lives in the distribution and elimination phases were 2.8 and 17.4 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,2.8,261838,DB00455,Loratadine
,2965043,disposition half-lives,"Its disposition half-lives in the distribution and elimination phases were 2.8 and 17.4 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,17.4,261839,DB00455,Loratadine
≥,22271705,half-life,Poor metabolizers or slow metabolizers of desloratadine were determined as individuals having a 3-OH-desloratadine to desloratadine exposure ratio lower than 10% or a desloratadine half-life ≥ 50 h.,Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271705/),h,50,262296,DB00455,Loratadine
,31897616,Cmax,"Further, the oral pharmacokinetic studies of LOR SMEDDS-SFN showed 4-fold and 9-fold increase in Cmax (503.2 ± 5.8 ng/mL) and oral bioavailability (20,274.8 ± 3711.0 ng·h/mL) for LOR compared to LOR-SFN combination respectively assuring the enhanced performance by the SMEDDS.",Efficacy and Pharmacokinetic Considerations of Loratadine Nanoformulations and its Combinations for Pancreatic Cancer Chemoprevention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31897616/),[ng] / [ml],503.2,263785,DB00455,Loratadine
,31897616,oral bioavailability,"Further, the oral pharmacokinetic studies of LOR SMEDDS-SFN showed 4-fold and 9-fold increase in Cmax (503.2 ± 5.8 ng/mL) and oral bioavailability (20,274.8 ± 3711.0 ng·h/mL) for LOR compared to LOR-SFN combination respectively assuring the enhanced performance by the SMEDDS.",Efficacy and Pharmacokinetic Considerations of Loratadine Nanoformulations and its Combinations for Pancreatic Cancer Chemoprevention. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31897616/),[h·ng] / [ml],"20,274.8",263786,DB00455,Loratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,8.7,265049,DB00455,Loratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,7.6,265050,DB00455,Loratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,8.6,265051,DB00455,Loratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],212.4,265052,DB00455,Loratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],469.5,265053,DB00455,Loratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],325.2,265054,DB00455,Loratadine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,21,267874,DB00455,Loratadine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,1.,267875,DB00455,Loratadine
